Physician profile
Sunwook Kim
NPI 1255474359
$94,230.89
in general payments reported to CMS, 2019-2025
29 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,330 · 2020: $266 · 2021: $5,129 · 2022: $43K · 2023: $11K · 2024: $10K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $9,300 · Travel and Lodging: $4,874 · Food and Beverage: $2,525 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,000.00 |
| Consulting Fee | $9,300.00 |
| Travel and Lodging | $4,874.17 |
| Food and Beverage | $2,524.98 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $78,953.18 | 2020-2025 | Gelpoint V-Path |
| Virtual Incision Corporation | $8,000.00 | 2025 | Mira |
| Intuitive Surgical, INC. | $4,060.06 | 2019-2021 | |
| Hologic Sales and Service, LLC | $814.79 | 2021-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System, Aptima |
| Abbvie INC. | $611.69 | 2019-2023 | |
| Arthrex, INC. | $273.12 | 2023-2025 | Arthrex |
| Astellas Pharma US INC | $211.88 | 2023 | Veozah |
| Momentis Surgical INC. | $178.67 | 2021 | |
| Lsi Solutions INC | $151.77 | 2023-2024 | Fornisee |
| Coloplast Corp | $142.02 | 2024 | |
| Biogen, INC. | $125.00 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $122.65 | 2023-2024 | Myfembree |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Exact Sciences Corporation | $63.02 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $54.47 | 2023 | Truclear |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $53.24 | 2023-2024 | |
| Exeltis, USA INC. | $44.07 | 2022-2024 | Slynd |
| Pfizer INC. | $38.17 | 2022-2023 | |
| Lupin INC. | $27.02 | 2019 | |
| Allotrope Medical, INC | $27.00 | 2022 | |
| Organon LLC | $26.52 | 2023-2025 | Nexplanon, Jada System |
| Bayer Healthcare Pharmaceuticals INC. | $24.59 | 2023 | |
| Inari Medical, INC. | $24.57 | 2020 | |
| Medical Device Business Services, INC. | $22.74 | 2025 | Harmonic |
| Convatec INC. | $18.01 | 2022 | |
| Minerva Surgical, INC | $17.89 | 2025 | |
| Abbott Laboratories | $17.42 | 2025 | Freestyle Libre |
| Therapeuticsmd, INC. | $15.15 | 2019 | |
| Smith+Nephew, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunwook Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.